George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
C7,
Good to have you back posting, feels like old times again with an SP to match!
Sorry to hear of your health issues and wish you all the best in terms of treatment, improvement or at least coping.
Violin commented on the journey we’ve been on. It has been a bit of a rollercoaster hasn’t it?
That got me thinking that shareholders here are like the people on a rollercoaster:
Some just won’t get on under any circumstances.
Some do it once and say “never again”
Some jump on and off having a different experience each time.
But others like it so much they never get off and just go round and round continually.
Ironically, waiting til you get to the top and then jumping off whilst tempting is not recommended!
ATB
I think the reality is that current holders will read every RNS thoroughly regardless of the title.
Similarly, those not invested won't read an RNS regardless of the title.
It is after all a legal regulation being fulfilled not a marketing campaign.
Sorry Cleanerworld,
It was indeed dragon who said move on. I was responding to C11's endorsement of that comment not you.
As I said to TF earlier, I do seem to be confused at the moment.
Once again, apologies.
Cleanerworld,
"I wouldn’t say it’s unreasonable, to suggest someone moves on, when they state they believe they’re invested in a “jam tomorrow” company."
Sorry, it is extremely impolite to tell someone to "move on" simply because you disagree with their view. If your confidence is so low as to be so sensitive to negativity, I suggest you filter everyone except fellow happy clappers.
Telling someone to sell is also wrong. Anyone is free to buy, hold, sell as they see fit and everyone is entitled to an opinion.
Many peoples expectations were not met. The delayed AGM and final accounts WERE a fiasco - orchestrated by the auditors. I accept that there are others who have no expectations who think everything is hunky dory.
But please, don't tell people to sell just because they have a different view to your own. An individual's investment decision is based on far more important factors than that.
Thanks. It has been rough alternating between shivering and sweating and accompanied by a banging headache.
The worst thing now is I have a horrendous bright red rash on my left shin, calf and ankle. Looks like I have my own cytokine storm going on down there.
TF,
Yes, I am fully up to date with all jabs and boosters. Whether that has helped or actually contributed to the rash I just don't know. At my age and with my medical conditions, not having the jabs would have been irresponsible. If I were 20 years younger I probably wouldn't have.
burble,
a couple of questions if i may:
1) do we know that a lower dose of cpi will cause less toxicity. a smaller dose of ****nic will still kill you.
2) how can we prove that scib1 in combination will be just as (or more) effective with a lower cpi dose. my understanding is that trials are approved for the standard dose of the approved drug (in this case cpi) and the second(unapproved) drug is subject to dose escalation.
I have to disagree with Crackin's comment that it is stupid to take up the open offer when you can (could) buy cheaper on the open market. Any existing shareholder would be stupid not to support the OO if they are in a position to do so. This will provide additional funding for Scancell which I'm sure they will put to good use.
I suspect a third of investors won't take up the offer, a third will and the other third will apply for twice their entitlement. So overall I'm expecting it to be fully subscribed.
The additional £2m is far more significant than a fraction of a penny on the buy in price.
POST
TF,
The term "big company" is so subjective it becomes irrelevant.
If we judge it on the number of employees, Scancell will possibly never be "big"
If we judge it on revenue, that could be a long way away.
If we judge it on market capitalisation, that could come anytime out of the blue.
If we judge it within its peer group - companies developing cancer immunotherapies - it's already a "big" company. Didn't professor Lindy Durrant describe Scancell as a "world leader in cancer immunology" at the recent AGM?
Miavoce,
I get where you are coming from, but if it was the case this was the only income for Scancell they would have to use part of it to fund the other drugs in the pipeline and further research.
Thinking about it however, the £10M or so ongoing costs wouldn't make much of a dent in £300m would it. So not "pure profit" but 97% profit.